Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review - PubMed (original) (raw)
Review
Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review
Gareth S Dulai et al. Gastroenterology. 2002 Jan.
Abstract
Background & aims: The public health impact of past screening and surveillance practices on the outcomes of Barrett's related cancers has not previously been quantified. Our purpose was to determine the prior prevalence of Barrett's esophagus in reported cases of incident adenocarcinoma undergoing resection, as an indirect measure of impact.
Methods: We performed a systematic review of the literature from 1966 to 2000. Studies were included if they reported: (1) the number of consecutive adenocarcinomas resected, and (2) the number of those resected who had a previously known diagnosis of Barrett's. We generated summary estimates using a random effects model.
Results: We identified and reviewed 752 studies. Twelve studies representing a total of 1503 unique cases of resected adenocarcinomas met inclusion criteria. Using a random effects model, the overall percentage of patients undergoing resection who had a prior diagnosis of Barrett's was 4.7% +/- 2.9%.
Conclusions: The low prior prevalence (approximately 5%) of Barrett's esophagus in this study population provides indirect evidence to suggest that recent efforts to identify patients with Barrett's-whether through endoscopic screening or evaluation of symptomatic patients-have had minimal public health impact on esophageal adenocarcinoma outcomes. The potential benefits of endoscopic surveillance seem to have been limited to only a fraction of those individuals at risk. These data thus provide a clear and compelling rationale for the development of effective screening strategies to identify patients with Barrett's esophagus.
Comment in
- Discussion on preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systemic review.
Gough M, Kelty C, Bird N, Majeed A, Ackroyd R. Gough M, et al. Gastroenterology. 2002 Sep;123(3):955; discussion 955. doi: 10.1053/gast.2002.35769. Gastroenterology. 2002. PMID: 12198729 No abstract available.
Similar articles
- Is Barrett's metaplasia the source of adenocarcinomas of the cardia?
Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M, Hinder RA, Bremner CG, DeMeester TR. Clark GW, et al. Arch Surg. 1994 Jun;129(6):609-14. doi: 10.1001/archsurg.1994.01420300051007. Arch Surg. 1994. PMID: 8204035 - Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophago-gastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II).
Ruol A, Merigliano S, Baldan N, Santi S, Petrin GF, Bonavina L, Ancona E, Peracchia A. Ruol A, et al. Dis Esophagus. 1997 Jul;10(3):190-5. doi: 10.1093/dote/10.3.190. Dis Esophagus. 1997. PMID: 9280078 Clinical Trial. - Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ, Wong RK. Cossentino MJ, et al. Semin Gastrointest Dis. 2003 Jul;14(3):128-35. Semin Gastrointest Dis. 2003. PMID: 14653412 Review. - Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus.
Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA. Visrodia K, et al. Aliment Pharmacol Ther. 2016 Oct;44(8):775-84. doi: 10.1111/apt.13783. Epub 2016 Aug 26. Aliment Pharmacol Ther. 2016. PMID: 27562355 Review. - Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP. Thrift AP. Curr Opin Gastroenterol. 2016 Jul;32(4):319-24. doi: 10.1097/MOG.0000000000000274. Curr Opin Gastroenterol. 2016. PMID: 27276368 Review.
Cited by
- Patient Knowledge, Risk Perception, and Barriers to Barrett's Esophagus Screening.
Kolb JM, Chen M, Tavakkoli A, Gallegos J, O'Hara J, Tarter W, Hochheimer CJ, Golubski B, Kopplin N, Hennessey L, Kalluri A, Devireddy S, Scott FI, Falk GW, Singal AG, Vajravelu RK, Wani S. Kolb JM, et al. Am J Gastroenterol. 2023 Apr 1;118(4):615-626. doi: 10.14309/ajg.0000000000002054. Epub 2022 Oct 11. Am J Gastroenterol. 2023. PMID: 36219171 Free PMC article. - Combined EsophaCap cytology and MUC2 immunohistochemistry for screening of intestinal metaplasia, dysplasia and carcinoma.
Zhou Z, Kalatskaya I, Russell D, Marcon N, Cirocco M, Krzyzanowski PM, Streutker C, Liang H, Litle VR, Godfrey TE, Stein L. Zhou Z, et al. Clin Exp Gastroenterol. 2019 May 15;12:219-229. doi: 10.2147/CEG.S186958. eCollection 2019. Clin Exp Gastroenterol. 2019. PMID: 31190949 Free PMC article. - A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett's esophagus screening in the community.
Sami SS, Dunagan KT, Johnson ML, Schleck CD, Shah ND, Zinsmeister AR, Wongkeesong LM, Wang KK, Katzka DA, Ragunath K, Iyer PG. Sami SS, et al. Am J Gastroenterol. 2015 Jan;110(1):148-58. doi: 10.1038/ajg.2014.362. Epub 2014 Dec 9. Am J Gastroenterol. 2015. PMID: 25488897 Free PMC article. Clinical Trial. - Barrett's esophagus: best practices for treatment and post-treatment surveillance.
Mansour NM, El-Serag HB, Anandasabapathy S. Mansour NM, et al. Ann Cardiothorac Surg. 2017 Mar;6(2):75-87. doi: 10.21037/acs.2017.03.05. Ann Cardiothorac Surg. 2017. PMID: 28446996 Free PMC article. Review. - Barrett's oesophagus and oesophageal cancer following oesophageal atresia repair: a systematic review.
Tullie L, Kelay A, Bethell GS, Major C, Hall NJ. Tullie L, et al. BJS Open. 2021 Jul 6;5(4):zrab069. doi: 10.1093/bjsopen/zrab069. BJS Open. 2021. PMID: 34370830 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous